Categories
Uncategorized

Edwards Lifesciences (EW), Stock Sinks as Market Gains: What you Should Know

Edwards Lifesciences (EW) closed the most recent trading day at $118.26, moving -1.83% from the previous trading session. This change lagged the S&P 500’s daily gain of 0.08%. Meanwhile, the Dow lost 0.56%, and the Nasdaq, a tech-heavy index, lost 0.42%. – Zacks Coming into today, shares of the medical device maker had gained 0.74%…

Edwards Lifesciences (EW) closed the most recent trading day at $118. 26, moving -1. 83% from the previous trading session. This change lagged the S&P 500’s daily gain of 0.08%. The Dow lost 0. 56%, and the Nasdaq, a tech-heavy index, lost 0.42%.

– Zacks

Shares of the medical device manufacturer had gained 0. 74% in the past month. In that same time, the Medical sector lost 4.1%, while the S&P 500 gained 0.22%.

Investors can expect strength from Edwards Lifesciences when it releases its next earnings report. Analysts expect Edwards Lifesciences will post earnings of $0. 54 per share. This would represent an 8% increase in year-over-year revenue. According to our most recent consensus estimate, quarterly revenue is expected to be $1. 35 billion, up 12. 96% from the year-ago period.

It is important to take note of the recent changes in analyst estimates for Edwards Lifesciences. These revisions are often based on the most recent short-term trends in business, which can change regularly. Positive estimate revisions can be viewed as a sign that the company is optimistic about its business outlook.

Our research has shown that these estimates changes are directly related to near-term stock price movements. To capitalize on this phenomenon, we created the Zacks Rank. This system considers these changes and provides a clear, practical rating model. The Zacks rank system ranges between #1 (Strong Buy), to #5 (Strong Seller). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0. 14% higher. Edwards Lifesciences currently has a Zacks Rank #3 (Hold).

Digging into valuation, Edwards Lifesciences currently has a Forward P/E ratio of 47.53. This represents a premium compared to its industry’s average Forward P/E of 44.02.

Meanwhile, EW’s PEG ratio is currently 3.39. The PEG ratio is similar to the P/E ratio but it also considers the stock’s expected earnings growth rate. Average PEG ratio for Medical – Instruments was 2. 52 at yesterday’s closing price. The Medical – Instruments sector is part of . This group has a Zacks Industry Rank of 168, putting it in the bottom 35% of all 250+ industries. The Zacks Industry Rank measures the strength of each industry group by measuring the Zacks Ranks of individual stocks within that group. Our research shows that the top 50% rated industries outperform the bottom half

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *